Aphios® Corporation, located in Woburn, MA, was founded in 1993 by Dr. Trevor Castor, Ph.D., the company's President and CEO.
Aphios is an environmentally-conscious biotechnology company whose primary goal is to pursue virus inactivation. In order to achieve this objective, the company developed a technology to disrupt viral particles through the application of SuperFluids™. Under Dr. Castor's leadership, the company serendipitously realized that by reverse engineering the technology to disrupt viral particles they could now create nanoparticles that can be suitably employed for drug solubilization and delivery.
Over the years, the strategic direction of the company has evolved from being a company focused solely on viral therapeutics to an organization that focuses on related technology diversification across drug solubility and delivery, thereby expanding the scope for innovative therapeutic administration.
Aphios Corporation is developing enabling SuperFluids™ technology platforms for improving the discovery, manufacturing, pathogenic safety and delivery of therapeutic drugs and utilizing these platforms to develop enhanced therapeutics for health maintenance and the treatment of human diseases with a focus on preventing and treating certain cancers, infectious diseases and Central Nervous System (CNS) disorders.
Aphios has been awarded several peer-reviewed, competitive SBIR Grants from NIH and NSF, and ATP grants from the NIST, Department of Commerce. Its enabling technology platforms, nanotechnologies and enhanced therapeutic products are covered by 36 issued US and international patents, and 22 pending patent applications. Aphios collaborates with multinational companies such as Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly, Baxter Healthcare, Sigma-Aldrich and leading academic institutions.
